Pharmacological applications of diacerein
A review
Abstract
IL-1β is one of the important IL-1 superfamily cytokines that shows crucial role in the pathogenesis of various inflammatory disorders like osteoarthritis, epidermolysis bullosa, psoriasis and type II diabetes. Dugs with IL-1βinhibitory effect can show promising results in these types of inflammatory disorders. Diacerein and its active metabolite rhein prevent the generation of active IL-1 and are consequently used to treat inflammatory conditions such as osteoarthritis, epidermolysis bullosa, psoriasis, and Type II diabetes.
Downloads
References
Cardoso CR, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care. 2017; 40(10), 1356-63.
Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998; 35(5), 347-59.
Kaur D, Kaur J, Kamal SS. Diacerein, its beneficial impact on chondrocytes and notable new clinical applications. Brazilian Journal of Pharmaceutical Sciences.2019; 8, 54.
Aigner T, Schmitz N, Salter DM. Pathogenesis and pathology of osteoarthritis. InRheumatology. 2015; 1, 1462-1476.
Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Annals of the rheumatic diseases. 1993; 52(12), 870-5.
Sohn DH, Sokolove J, Sharpe O, Erhart JC, Chandra PE, Lahey LJ, Lindstrom TM, Hwang I, Boyer KA, Andriacchi TP, Robinson WH. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis research & therapy. 2012; 14(1), 1-3.
Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shanebeck K. Interleukin 1 signaling occurs exclusively via the type I receptor. Proceedings of the National Academy of Sciences. 1993; 90(13), 6155-9.
Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. InSeminars in immunology. 2013; 25(6), 389-393.
Piccioli P, Rubartelli A. The secretion of IL-1β and options for release. InSeminars in immunology. 2013, 25(6), 425-429.
Kawai T, Akira S. TLR signaling. InSeminars in immunology. 2007; 19(1), 24-32.
Fan Z, Bau B, Yang H, Soeder S, Aigner T. Freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin‐1β. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2005; 52(1), 136-43.
Pfander D, Heinz N, Rothe P, Carl HD, Swoboda B. Tenascin and aggrecan expression by articular chondrocytes is influenced by interleukin 1β: a possible explanation for the changes in matrix synthesis during osteoarthritis. Annals of the rheumatic diseases. 2004; 63(3), 240-4.
Venkatesan N, Barre L, Benani A, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M. Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair. Proceedings of the National Academy of Sciences. 2004; 101(52), 18087-92.
Shakibaei M, John T, Seifarth C, Mobasheri AL. Resveratrol inhibits IL‐1β–induced stimulation of caspase‐3 and cleavage of PARP in human articular chondrocytes in vitro. Annals of the New York Academy of Sciences. 2007; 1095(1), 554-63.
Moldovan F, Pelletier J, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1β and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis and Cartilage.2000; 8(3), 186-96.
Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. The Journal of rheumatology.1998; 25(4), 753.
Yaron M, ShirazI I, Yaron I. eAnti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis and Cartilage.1999; 7(3), 272-80.
Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. The Journal of rheumatology. 1998; 25(12), 2417-24.
Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis and cartilage. 2007, 15(6), 605-14.
Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, Wigler I, Rosner IA, Beaulieu AD. Efficacy and safety of diacerein in osteoarthritis of the knee: A double‐blind, placebo‐controlled trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2000; 43(10), 2339-48.
Bruyère, O., Cooper, C., Pelletier, J.P., Branco, J., Brandi, M.L., Guillemin, F., Hochberg, M.C., Kanis, J.A., Kvien, T.K., Martel-Pelletier, J. and Rizzoli, R. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). In Seminars in arthritis and rheumatism. 2014; 44(3), 253-263.
Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature reviews Drug discovery. 2014; 13(6), 465-76.
Herder C, Dalmas E, Böni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends in Endocrinology & Metabolism. 2015; 26(10), 551-63.
Böni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses JA, Kerr-Conte J, Pattou F, Halban PA, Weir GC, Donath MY. Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. The Journal of Clinical Endocrinology & Metabolism. 2008; 93(10), 4065-74.
Donath MY. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia. 2016; 59(4), 679-82.
Gustafson B. Adipose tissue, inflammation and atherosclerosis. Journal of atherosclerosis and thrombosis. 2010; 17(4), 332-41.
Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ, Ryu MJ, Ko YB, Lee MA, Lee J, Ku BJ. The roles of adipokines, proinflammatory cytokines, and adipose tissue macrophages in obesity-associated insulin resistance in modest obesity and early metabolic dysfunction. PloS one. 2016; 11(4), e0154003.
Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, de Lima Zollner R. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. International immunopharmacology. 2008; 8(6), 782-91.
Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araujo TG, Santos-Silva JC, Zollner RL, Boechat LH, Carvalheira JB, Prada PO. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. 2011; 152(11), 4080-93.
Du H, Shao J, Gu P, Lu B, Ye X, Liu Z. Improvement of glucose tolerance by rhein with restored early-phase insulin secretion in db/db mice. Journal of endocrinological investigation. 2012; 35(6), 607-12.
Liu J, Chen Z, Zhang Y, Zhang M, Zhu X, Fan Y, Shi S, Zen K, Liu Z. Rhein protects pancreatic β-cells from dynamin-related protein-1–mediated mitochondrial fission and cell apoptosis under hyperglycemia. Diabetes. 2013; 62(11), 3927-35.
Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Experimental and clinical endocrinology & diabetes. 2007; 115(09), 571-6.
Zheng JM, Zhu JM, Li LS, Liu ZH. Rhein reverses the diabetic phenotype of mesangial cells over‐expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. British journal of pharmacology. 2008; 153(7), 1456-64.
Sheng X, Wang M, Lu M, Xi B, Sheng H, Zang YQ. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. American Journal of Physiology-Endocrinology and Metabolism. 2011; 300(5), E886-93.
Lin YJ, Hu G, Li KJ, Zhao YF, Wei J, Zhen YZ. The protection of Rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Archives of pharmacal research. 2015; 38(5), 885-92.
Cardoso CR, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care. 2017; 40(10), 1356-63.
Christophers E. Psoriasis− epidemiology and clinical spectrum. Clinical and experimental dermatology. 2001; 26(4), 314-20.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013; 133(2), 377-85.
Gibbs SA. Skin disease and socioeconomic conditions in rural Africa: Tanzania. International journal of dermatology. 1996; 35(9), 633-9.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology. 2014; 70(3), 512-6.
Ortonne J., Chimenti S., Luger T., Puig L., Reid F., Trueb R.M. Scalp psoriasis: European consensus on grading and treatment algorithm. J. Eur. Acad. Dermatol. Venereol. 2009; 23, 1435–1444
Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6), 1475.
Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. The British journal of dermatology. 1999; 140, 1-7.
Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunology today.1999; 20(1), 40-6.
Das RP, Jain AK, Ramesh V. Current concepts in the pathogenesis of psoriasis. Indian J Dermatol. 2009; 54(1), 7-12.
Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer HD. The inflammasome mediates UVB-induced activation and secretion of interleukin-1β by keratinocytes. Current Biology. 2007; 17(13), 1140-5.
Murphy JE, Robert C, Kupper TS. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. Journal of Investigative Dermatology.2000; 114(3), 602-8.
Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. The Journal of Immunology.2006; 176(7), 3877-83.
Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. 2009; Nature immunology. 10(3), 241-7.
Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y, Fleming C, Hu X, Zhang HG, Weichselbaum R, Fu YX. A critical role of the IL-1β–IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. Journal of Investigative Dermatology. 2019; 139(1), 146-56.
Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta‐analysis of observational studies. Journal of the American Heart Association. 2013; 2(2), e000062.
Kaplan MJ. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vascular health and risk management. 2008; 4(6), 1229.
Barlic J, Murphy PM. Chemokine regulation of atherosclerosis. Journal of leukocyte biology. 2007; 82(2), 226-36.
Wong D, Dorovini-Zis K. Expression of vascular cell adhesion molecule-1 (VCAM-1) by human brain microvessel endothelial cells in primary culture. Microvascular research. 1995; 49(3), 325-39.
Mohan GC, Zhang H, Bao L, Many B, Chan LS. Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells. PloS one.2017; 12(3), e0173981.
Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. The Journal of Immunology.2013; 190(5), 2252-62.
Butcher M, Galkina E. Murine aortic vascular cells produce IL-17C and support inflammation in atherosclerosis. (CCR6P. 271).
Morley SM, D'Alessandro M, Sexton C, Rugg EL, Navsaria H, Shemanko CS, Huber M, Hohl D, Heagerty AI, Leigh IM, Lane EB. Generation and characterization of epidermolysis bullosa simplex cell lines: scratch assays show faster migration with disruptive keratin mutations. British Journal of Dermatology.2003; 149(1), 46-58.
Jeřábková B, Marek J, Bučková H, Kopečková L, Veselý K, Valíčková J, Fajkus J, Fajkusová L. Keratin mutations in patients with epidermolysis bullosa simplex: correlations between phenotype severity and disturbance of intermediate filament molecular structure. British Journal of Dermatology. 2010; 162(5), 1004-13.
Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, Hainzl S, Hintner H, Bauer JW. The pathogenetic role of IL-1β in severe epidermolysis bullosa simplex. The Journal of investigative dermatology.2013; 133(7), 1901-3.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
